The UK medicines regulator has started its review of Ultragenyx's gene therapy for Sanfilippo syndrome type A, and Ultragenyx says NICE will run its evaluation alongside it. The product was approved by the FDA on 17 September 2026 on evidence from a single-arm study, and carries a US list price of $3.95 million. For UK access teams, this is a live test of how far NICE's Highly Specialised Technologies (HST) methods can carry a one-time therapy for a fatal childhood disease when no randomised comparator exists.

Where the review stands

The MHRA accepted the marketing authorisation application on 28 October 2026. Ultragenyx says it has agreed to schedule the NICE evaluation to align with that review, aiming for a NICE decision close to any licence. The EMA review began in October 2026. UX111 (rebisufligene etisparvovec, brand name Fayuvi in the US) remains investigational in the UK.

NICE's Prioritisation Board has already routed the product to the Highly Specialised Technologies programme after finding it met all four HST criteria. The NICE project page shows a draft scope with established clinical management as the comparator, a submission deadline expected around mid-November 2026, and no publication date yet.

What the evidence is

The FDA's own summary describes an open-label, single-arm, multicentre study. Efficacy was measured as the mean change in cognitive scores in children aged 2 to 5 years, set against an untreated historical control cohort. Treated children maintained or improved cognitive function, where the expected natural course is plateau and decline.

That is a credible signal for a disease where Ultragenyx cites a median life expectancy of 15 years. HTA committees will probe the evidence package in three places:

  • The control arm is external. Every cognitive difference depends on how well the natural history cohort matches the treated children in age, baseline function and rate of decline.
  • Long-term durability is unknown. A one-time therapy priced up front needs a defensible assumption about how long the effect lasts, and a lifetime model will extrapolate well beyond any observed follow-up.
  • Safety carries a long tail. The FDA flags thrombotic microangiopathy and a potential long-term risk of tumour development from genomic integration, a risk it notes is shared with other AAV-based therapies.

Price and the HST threshold

Ultragenyx has set a US list price of $3.95 million. The same report says roughly 1 in 70,000 children is born with Sanfilippo syndrome each year, so the population is very small and the budget impact in any one health system is modest. The question for NICE is the cost per QALY.

The HST programme applies a sliding scale of £100,000 to £300,000 per QALY, rising with the QALYs gained. Where a product lands depends on the lifetime QALY gain the model credits, which in turn depends on the durability assumption and on how the natural history cohort is used. A product like this can look very different at 10 and at 30 QALYs gained, so those inputs deserve more scrutiny than the headline price.

What it means for market access teams

  • Align the evidence plan with the licence clock. With NICE running in step with the MHRA, the dossier and the regulatory file will be read together. Reviewers will notice differences between the two on endpoints or population.
  • Treat the natural history comparison as a primary analysis. Pre-specify the matching approach and run sensitivity analyses on cohort selection, because committees will test it.
  • Model durability explicitly. Present scenarios for waning and for lifelong effect, and say what follow-up data would narrow the range.
  • Plan for outcomes-based terms. A one-time price and uncertain durability make a managed access agreement with data collection a realistic outcome, so have the commercial and data-collection design ready before the committee meets.
  • Watch the read-across. Other sponsors of one-time CNS gene therapies for rare paediatric disease will take their cues from how NICE treats a single-arm package here.

To discuss how a single-arm evidence package and a one-time price would fare under HST, get in touch or see our sector expertise in rare and orphan disease.